Intellia Therapeutics (NTLA) Tops Q3 EPS by 12c

Intellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($1.38), $0.12 better than the analyst estimate of ($1.50). Revenue for the quarter came in at $12 million versus the consensus estimate of $12.45 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Exyn Technologies reports Q1 2026 results after Nasdaq IPO
• Retail investors largely unaware of SEC semiannual reporting proposal